Results 1 to 10 of about 16,918 (164)
Epidemiology and cardiometabolic care in adults with ASCVD and high 10-year ASCVD risk: 2021 WHO STEPS study in Iran [PDF]
Scientific ReportsAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality and health burden worldwide. We aimed to assess ASCVD epidemiology, 10-year risk, and cardiometabolic care using nationally representative data in Iran.
Hossein Farrokhpour +19 more
doaj +2 more sources
Relationship of vegetarianism with body weight loss and ASCVD
Frontiers in NutritionIntroductionThe association between a plant-based diet and weight loss and atherosclerotic cardiovascular disease (ASCVD) has not been fully elucidated. We performed a pooled analysis and Mendelian randomization (MR) analysis to investigate this question.MethodsWe searched for randomized controlled trials on the effects of a plant-based diet on weight ...
Yani Xu +5 more
exaly +4 more sources
Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA [PDF]
American Heart Journal PlusStudy objective: Systemic inflammation increases the risk of cardiovascular events and is often present in patients with atherosclerotic cardiovascular disease (ASCVD), particularly in those who also have chronic kidney disease (CKD).
Michael G. Nanna +7 more
doaj +2 more sources
Non-high-density lipoprotein (non-HDL) cholesterol in adolescence as a predictor of atherosclerotic cardiovascular diseases in adulthood [PDF]
Reviews in Cardiovascular Medicine, 2021 Defined as the total cholesterol minus high-density lipoprotein (HDL), non-HDL cholesterol has been increasingly acknowledged as a measure of risk estimation for developing atherosclerotic cardiovascular diseases (ASCVD).
Saeed Shoar +7 more
doaj +1 more source
The ins and outs of lipoprotein(a) assay methods
Archives of Medical Science: Atherosclerotic Diseases, 2023 Pathophysiological, epidemiological and genetic studies convincingly showed lipoprotein(a) (Lp(a)) to be a causal mediator of atherosclerotic cardiovascular disease (ASCVD).
Maryam Heydari +5 more
doaj +1 more source
Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
EXCLI Journal : Experimental and Clinical Sciences, 2022 Atherosclerotic cardiovascular disease (ASCVD) stands amongst the leading causes of mortality worldwide and has attracted the attention of world’s leading pharmaceutical companies in order to tackle such mortalities.
Mohd Waiz +2 more
doaj +1 more source
Environmental Health and Preventive Medicine, 2023 Background: Stair climbing is a readily available form of physical activity with potential cardioprotective merits. Herein, we investigated the association between stair climbing and atherosclerotic cardiovascular disease (ASCVD) incidence among Japanese
Ahmed Arafa +2 more
doaj +1 more source
World Heart Federation Cholesterol Roadmap 2022
Global Heart, 2022 Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally.
Kausik K. Ray +23 more
doaj +1 more source
Liang you shipin ke-ji, 2022 In this study, network pharmacology and molecular docking methods were used to explore the mechanism of components in walnut kernels in preventing atherosclerotic cardiovascular disease (ASCVD).
XU Zi-wu +4 more
doaj +1 more source
Highlights in ASCVD Primary Prevention for 2021
Journal of the American Heart Association, 2022 This review examines key studies published in 2021 that are related to primary prevention of atherosclerotic cardiovascular disease (ASCVD). Major randomized clinical trials (RCTs) concerning traditional risk factors or ASCVD events, meta‐analyses, and key observational studies related to primary prevention of ASCVD were considered. The review includes
Tamar S. Polonsky +4 more
openaire +3 more sources